Microbot Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Microbot Medical şirketinin toplam hissedar öz sermayesi $3.8M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $5.2M ve $1.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$4.34m
Eşitlik	US$3.81m
Toplam yükümlülükler	US$1.40m
Toplam varlıklar	US$5.21m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CY9D 'nin kısa vadeli varlıkları ( $5.0M ) kısa vadeli yükümlülüklerini ( $1.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: CY9D şirketinin kısa vadeli varlıkları ( $5.0M ) uzun vadeli yükümlülüklerini ( $29.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CY9D borçsuzdur.

Borcun Azaltılması: CY9D un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CY9D şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CY9D un, serbest nakit akışı her yıl % 9.1 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Microbot Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. announced delayed 10-Q filing

Recent updates

New major risk - Financial position

Microbot Medical Inc., Annual General Meeting, Dec 17, 2024

Microbot Medical Inc. Announces Successful Completion of Its Pivotal Human Clinical Trial

Microbot Medical Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Microbot Medical Inc. Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System

Microbot Medical Inc. Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center

Microbot Medical Enrolled the First Patient in Its Pivotal Human Clinical Trial

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $4.819905 million.

Microbot Medical Inc. announced that it has received $1.762502 million in funding

New major risk - Shareholder dilution

Microbot Medical Inc. has completed a Follow-on Equity Offering in the amount of $2.350004 million.

Microbot Medical Inc. has filed a Follow-on Equity Offering in the amount of $2.350004 million.

New major risk - Share price stability

Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving All Associated Legal Matters

New major risk - Shareholder dilution

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met

Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from Its Pivotal Pre-Clinical Study

Microbot Medical Inc. Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against Company

Microbot Medical Inc. Announces Successful Initial Outcomes from its Pivotal Pre-Clinical Study with the LIBERTY Robotic Surgical System

Microbot Medical Inc., Annual General Meeting, Nov 02, 2023

Microbot Medical Inc. Appoints Francois H. Cornelis to its Scientific Advisory Board

Microbot Medical Inc. Announces the Expansion of its Global IP Portfolio by Receiving a Grant of Protection from the Japan Patent Office

New major risk - Shareholder dilution

Microbot Medical Receives Non-Dilutive Grant from the Israel Innovation Authority Supporting the Development of the Manufacturing Process for Its Endovascular Surgical Robotic System

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

Microbot Medical Inc. announced delayed 10-Q filing

Microbot Medical Initiates Preparations for First-In-Human (Fih) Cases in Brazil for the Liberty® Robotic System

Microbot Medical Inc. Announces Final Data from Its Recent Animal Study

Microbot Medical Inc. Announces Liberty Robotic System Surpasses 100Th Catheterization

Microbot Medical Inc.’s Proprietary LIBERTY® Robotic System Receives Third Patent Allowance in Israel

Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance

High number of new directors

Microbot Medical Inc. Receives Additional Patent Allowance in Israel for the LIBERTY(R) Robotic System

Microbot Medical Inc Appoints Thierry Jacques De Baère to its Scientific Advisory Board

Microbot Medical Accomplishes the Next-Step in the Regulatory Process for the Liberty® Robotic System

Microbot Medical Completes Glp Animal Study for the LIBERTY Robotic System

Microbot Medical Receives Patent Allowance in Israel for the Liberty® Robotic System

Microbot Medical Inc. (NasdaqCM:MBOT) entered into an Asset Purchase Agreement to acquire Assets from Nitiloop.

Microbot Medical Inc. Announce Strategic Addition to Scientific Advisory Board Appointment

Microbot Medical Inc. Announces Ripal T. Gandhi Has Joined Its Scientific Advisory Board

Microbot Medical Inc. Announces Vincent Vidal Has Joined Its Scientific Advisory Board

Microbot Medical Commences its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

Microbot Medical Inc. Appoints Sebastian Flacke to its Scientific Advisory Board

Microbot Medical Inc. Medical Secures Design Patent Grant in Europe for the LIBERTY Robotic System

Microbot Medical Confirms GLP Pre-Clinical Trial Is on Track to Commence Later This Month

Microbot Medical Inc., Annual General Meeting, Sep 21, 2022

High number of new directors

High number of new directors

Microbot Medical Inc. Announces Executive Changes

Microbot Medical Secures Third Patent for the LIBERTY® Robotic System in the United States

Microbot Medical Inc. Secures Patent Allowance in China and Third Global Jurisdiction in 2021 to Recognize Novelty of ‘One & Done’ Technology

New 90-day high: €8.75

Microbot Medical Announces Successful Outcome of Its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt

New 90-day high: €7.00

Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with Liberty Robotic System

New 90-day low: €5.55

Microbot Medical Inc. Announces Successful Animal Study Utilizing Its Liberty™ Robotic System

New 90-day low - €5.40

New 90-day high - €6.90

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin